Abstract Transglutaminase 2 (TG2) is a multifunctional member of an enzyme family: it modifies glutamine residues by cross-linking proteins and incorporating primary amines into them, has protein disulphide isomerase and protein kinase activities, mediates trans-membrane signal transduction and interactions between cell surface proteins and the extracellular matrix. These unusual multiple roles encoded into one polypeptide chain suggest that genomic variations in the TGM2 gene should be limited. Indeed, the available information in databases shows that unlike in the case of most other transglutaminases there are no common single nucleotide polymorphisms in exons of human TGM2. We collected data on and produced some of the rare genetic variants of TGM2 by site directed mutagenesis and found that some were less stable than the most abundant (wild type) enzyme variant and the majority had deficient transamidating activity. Further studies are required to clarify the pathologic significance of these rare TGM2 alleles in the human population.
Introduction
Transglutaminase research started more than five decades ago when Waelsch and co-workers observed a Ca 2? -dependent activity in liver extracts incorporating primary amines into proteins (Sarkar et al. 1957; Mycek et al. 1959 ). In the sixties, there were two important developments. First, the chemical nature of the cross-link formed in fibrin (Laki and Lóránd 1948) by blood coagulation factor XIIIa, a plasma transglutaminase (Loewy 1968) , was revealed (Pisano et al. 1968; Matacić and Loewy 1968; Lorand et al. 1968) . Second, the purification of tissue transglutaminase (later named transglutaminase 2; TG2) from guinea pig liver could be achieved (Folk and Cole 1966) in the NIH laboratory of Jack Folk, opening the way to the characterization of its enzymatic properties in details; the findings were summarized in the early seventies by Folk and Chung providing a basis of further developments in the field (Folk and Chung 1973) . In the pioneering TG2 experiments, and even later works with human transglutaminase 2 obtained from endothelial, red blood or other types of cells, it was assumed that the studied enzyme preparation represented a reproducibly obtainable homogenous protein population with the same amino acid sequence. After the completion of the human genome project and the availability of the HapMap (Thorisson et al. 2005 ) and other databases, it became evident that the vast majority of our proteins are polymorphic due mainly-but not exclusively-to single nucleotide polymorphism (SNP). The data presented by the 1000 Genomes Project Consortium (2010) have established the normal de novo mutation rate to be *1.1 9 10 -8 bp for a human haploid genome. Therefore, differences amounting to several million SNPs exist between the genome of any two individuals, of which tens of thousands are in protein coding exons. As a consequence, proteins encoded by the two parental chromosomes may differ significantly due to their individual polymorphism. The inherited rare genetic variations (most often SNPs) in the Mendelian disorder genes result in defective proteins leading to severe pathologic conditions in either their homo-or heterozygous forms. Examples in the transglutaminase protein family include the life threatening bleeding syndrome as a consequence of any of the more than 70 reported disease causing mutations of FXIIIa (Duckert et al. 1960; Karimi et al. 2009 ) and lamellar ichtiosis in cases of TGM1 mutations (Huber et al. 1995) . No such genetic mutation of TG2 has been reported so far. Most of our genes also have common variants and the significance of these SNPs have been the subject of a large number of genome wide association studies to reveal their contribution to or role in multi-factorial complex diseases. For example, the Val34Leu SNP of FXIIIa (25% prevalence in whites) provides a moderate protection against coronary artery disease (Muszbek et al. 2010) . Regarding TG2 systemic analysis of its polymorphisms has not been carried out yet.
In this paper, based on population genetic data (NCBI, Uniprot, HapMap, Ensemble, 1000 Genom datadases, Complete Genomics), we present the sequence of the most abundant (wild type) TG2 protein sequence and provide an overview of its so far found SNPs. Several of the TGM2 mutant forms have been produced and tested in biochemical assays. We compare the prevalence of TGM2 SNPs to those in other members of the transglutaminase family and discuss the possible reasons of the surprisingly low frequency of genetic variations in the protein coding sequence of TGM2.
Materials and methods

Databases and bioinformatic background
We used the standard websites of the NCBI, UniProt, HapMap, Ensembl (Galperin and Cochrane 2011) , 1000 Genome and Complete Genomics databases for browsing the data and retrieving the relevant sequences. The 1000 Genomes data frequencies were extracted from the VCF file using the vcftools program (Danecek et al. 2011) . For analyzing the Complete Genomics data (Drmanac et al. 2010) , the REFSEQ gene variation tables of the high coverage sequencing of 46 individuals (diversity panel) were downloaded. The relevant diversity data were extracted from these tables using BASH shell scripts.
Transglutaminase enzyme preparations
The cloned (Gentile et al. 1991) and variant recombinant human TG2s were expressed in N-terminally (His) 6 -tagged form and were purified by Ni-NTA affinity chromatography as described previously (Király et al. 2009 ). TG2 variants were constructed based on the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) and were checked by restriction analysis and DNA sequencing (ABI PRISM). The protein concentration was determined using the Bradford method (Bio-Rad, München, Germany). The purity of proteins was checked by Coomassie BB staining of SDS-polyacrylamide gels and by western blots.
Antibody-binding assays
Antigenicity and functional purity of TG2 proteins were determined by direct ELISA using G92 (G92.1.2; TrejoSkalli et al. 1995; 1:3,000) , CUB7402 (NeoMarkers, Fremont, CA, USA; 1:2,000), TG100 (NeoMarkers; 1:2,000) mouse monoclonal anti-TG2 and human coeliac antibodies as described earlier (Király et al. 2009 ). The wells were coated with 0.5 lg protein for 1 h at 4°C. After washing, the antibody solutions were incubated in the wells for 1 h at room temperature. The bound antibodies were detected using anti-mouse IgG/HRP or anti-human IgA IgG/HRP antibodies and TMB substrate.
Fibronectin binding
The fibronectin-binding property of the variants was tested using a direct ELISA assay. The wells were coated with 0.3 lg fibronectin in carbonate buffer pH 9.6 at 4°C for 1 h. After washing, 0.5 lg TG2 variant was incubated in the wells for 1 h at room temperature. The bound TG2 variants were detected using G92 (1:3,000) or CUB7402 (1:2,000) monoclonal antibodies and then anti-mouse IgG/ HRP (1:5,000, Sigma) and TMB substrate.
Measurement of transglutaminase activity
The microtiter plate assay based on the incorporation of 5-(biotinamido)pentylamine (Molecular Probes, Invitrogene) into immobilized N,N-dimethylated casein (DMC) was used as described before (Király et al. 2009 ). The fibronectin bound TG2 activity assay was performed as published earlier (Király et al. 2006) . Shortly, the wells were coated with 100 ll of 1 mg/ml human fibronectin in carbonate buffer pH 9.6 for 1 h at room temperature. After washing, the wells were coated with 3 lg recombinant enzyme in buffer A, then incubated with 200 ml of 1 mM 5-(biotinamido)-pentylamine substrate in 0.1 M Tris-HCl buffer, pH 8.5 containing 5 mM CaCl 2 , 10 mM DTT. Amine incorporation was detected as in the conventional method.
Results and discussion
The reference sequence of wild type transglutaminase 2 Transglutaminase 2 was first cloned in the laboratory of Peter Davies (Gentile et al. 1991) . The reference TGM2 sequence in the Ensemble database (obtained after the completion of the genome project) is shown in Fig. 1a . Comparing the two, five non-synonymous differences are seen in the former and we realized that these variants are also listed in the UniProt database as sequence conflicts (Fig. 1b) . The TGM2 cDNA construct used in our and many other laboratories is the firstly cloned cDNA originating from the Davies' lab. After sequencing this cDNA (ABI PRISM) several times, we found that it has the reference nucleotide sequence and not the conflicting one at four of the five disputed sites. The lower reliability of the classical sequencing technique used 20 years ago probably explains this discrepancy. Until this time there has been no reported genome sequence which contains any of the four nonsynonymous alleles. There is one exception, however, it is Gly224 in the Gentile sequence as opposed to Val224 in the reference sequence. We have validated this variant by re-sequencing the Gentile cDNA several times and suspect that it is either a mutation in the genome of the person from where TG2 was originally cloned or a mutation generated during the cloning procedures. It should be clarified whether this difference has any functional significance since to our knowledge many of the published transfection, recombinant and structural studies in the last two decades have been carried out using this cDNA, which is not the most frequent variant of the enzyme. Silent changes may in turn alter the expression level of TG2. Therefore, we have also analyzed the validity of such variants of the Gentile cDNA and found only one silent nucleotide change (in the triplet coding for Leu291), which could be confirmed as different from the reference sequence (Fig. 1b) .
Due to the above mentioned differences, we also have analyzed the available data (allele frequency of the single nucleotide changes) of the 1000 Genome database and Complete Genomics high coverage sequencing diversity panel results. These databases provide the newest, high fidelity sequence data. The comparison of these sequences confirms that the TGM2 reference sequence, which can be found in the Ensemble database, is indeed by far the most common haplotype of the TGM2 gene (see also data and discussion in the next and the fourth section).
SNPs in the TGM2 gene
At the time of writing the present article, 365 SNPs have been reported in the databases for the 38 kb TGM2 gene. Of these 34 SNPs are in the coding region, 18 are nonsynonymous mutations (Table 1) only in single genome): they occur in low frequency in the population and all are heterozygous. The analysis of the 1000 Genomes database also confirms that the frequency of the non-synonymous changes in TGM2 is very low while it has synonymous SNPs with average frequency. It should be noted that the databases contain some controversial data. Some of the SNPs are listed differently in the databases and sometimes the frequency value of the same SNP varies from one database to the other. Some SNPs have identification number but their heterozygosity value is 0.000 and in the population genetic data there is no chromosome which contains the particular variant (e.g. in the NCBI database rs146621816, rs139974885).
In the literature, three missense mutations (Asn333Ser, Met330Arg and Ile331Asn) were described in patients of Maturity Onset Diabetes of the Young (MODY) or early onset type 2 diabetes. These variants have impaired transglutaminase activity (TGase) suggesting that enzymatic activity of TG2 can play a role in disorders of glucose metabolism (Porzio et al. 2007; Bernassola et al. 2002) . However, there is no direct evidence that these mutations contribute to the development of diabetes in these patients. In a British population, eight non-coding SNPs across the TGM2 gene were genotyped and it was suggested that the detected variants were associated with schizophrenia and TGM2 may have a role in the development of this mental disease (Bradford et al. 2009 ). In another study, a major fraction of human protein coding genes was examined in breast and colorectal cancer (Sjöblom et al. 2006 ) to determine the spectrum and extent of somatic mutations; TGM2 was one of the genes with a somatic mutation (Gly660Val).
Functional consequence of TG2 mutations
Based on the data obtained from the databases between 2009 and 2010, 11 variants or mutants were produced in our laboratory by site directed mutagenesis. The studied variants were selected on the basis of some predictions for the potential effect of the amino acid change by comparing TGM2 to other transglutaminase family members and expecting that some SNPs in regions which are well conserved in the family may lead to serious functional defects while others, for example in the N terminal part, could cause just small deviances from the wild type protein. We predicted that SNPs close to the Ca 2? -binding sites can also cause serious functional defects.
After protein expression and one step Ni-NTA affinity purification, the yield and purity of the variants were determined (Fig. 2) . Although each variant could be expressed in a bacterial system, the yield and purity of the protein preparations were different. The Gly660Val mutant and FS153-169 double frame shift variants show lower purity and yield. In the case of the FS153-169 variant, this is not surprising because in our previous work, when this region was modified by mutations, the stability and purity of the expressed proteins were also less compared to the wild type enzyme and other mutants (Király et al. 2009 ). This region of TG2 could be responsible for the stabilization of the protein or its proper folding.
Before studying the functional properties of the TG2 variants, three monoclonal antibodies were used to compare their folding and binding properties on a microtiter plate (Fig. 3a) . The G92 antibody recognizes the N-terminal part of TG2 (Trejo-Skalli et al. 1995) , the CUB7402 (Epitope: aa447-478) and TG100 (Epitope: aa447-538) reacts with the catalytic core domain of TG2. In the case of G92 and CUB7402 antibodies, we could not see significant decrease in their binding to the mutant TG2. For the TG100 antibody, the Arg436Thr and Pro536Ser variants showed slight, while the Gly660Val mutant and FS153-169 variant slight but significant decrease in the antibody binding. The structural change in the molecules may alter the antibody-binding region or can decrease the stability of the variants.
It is known that TG2 plays a role in coeliac disease where it is the main antigen. The coeliac antibody binding of the mutants was also tested by ELISA (Fig. 3b) . The Arg214His and Pro536Ser variants show slight while the Gly660Val and FS153-169 ones significant decrease in antibody binding. The lowest antibody binding was found in the case of the FS153-169 variant. There is a sequence overlap between the FS153-169 variant and the S4 Ca 2? -binding site mutants produced in our previous work (Király et al. 2009 ) where we also observed significant decrease in coeliac antibody binding. The present observation confirms that this region contains an important anchor point for the autoantibodies to bind TG2.
Since TG2 has a significant role in scaffolding processes at the extracellular side of the cells and its interaction with fibronectin has a crucial role in this function, the fibronectin-binding property of the variants was also tested by an ELISA method (Fig. 4) . The variants bound fibronectin similarly to the un-modified enzyme, except the Asp389Asn and FS153-169 variants which exhibited decreased but not totally lost binding.
Finally, we measured transglutaminase activity of the variants in either their free or fibronectin bound form (Fig. 5) . The Arg76His, Pro78Gln, Pro78Arg variants showed activity comparable to the un-modified enzyme. The Arg214His and FS153-169 variants lost their transglutaminase activity in both assays. Asp389Asn, Arg436Thr and Gly660Val variants had very low transglutaminase activity (under 10% compared to wild type) using the conventional microtiter plate method but they had significantly higher transglutaminase activity when the enzyme was bound to fibronectin. Actually, in case of the other variants also higher transamidase activity was observed when they were bound to fibronectin. This suggests that fibronectin binding may improve stability of the active conformation of TG2 variants.
The results confirmed our functional prediction since the functionally defective variants have amino acid change in well conserved regions or close to the Ca 2? -binding sites of TG2. Since most TG2 variants with non-synonymous changes in exon sequences result in defective proteins it is likely that their appearance in affected individuals may have pathologic consequences. They may disturb cellular and tissue functions when are manifested in both TGM2 alleles. No cases like that have been described so far. The pathologies observed in TG2 knockout mice, e.g. diabetes (Bernassola et al. 2002) and autoimmunity (Szondy et al. 2003) , may give a clue to what to expect in such genetic cases if ever occurred. Somatic mutations may also lead to TG2 deficiency in cellular lineages or tumors contributing to tissue and disease specific malfunctions. Heterozygosity may also contribute to the development of complex diseases, for example, the missense mutations to the onset of MODY.
Even at the present stage of genomic technologies, it is a challenging task to prove association of rare frequency mutations with diseases; large cohorts, in the range of tens of thousands participants are needed to assess their contribution to pathologic phenotypes. However, recent developments in fast and precise DNA sequencing methods and the personal medicine approaches will open new possibilities to clarify the role and significance of rare SNPs, including the TG2 variants reported here, in various human pathologies.
Comparison of the frequency of genetic variations in genes of the transglutaminase family
In the Ensemble and 1000 Genomes database more than 100 single nucleotide changes are reported for FXIIIA and TGM1 and most of these are also listed as rare mutations in The Human Gene Mutation Database (http://www.hgmd. org) having causative roles in severe diseases such as FXIIIa deficiency with bleeding disorders (F13A1 mutants) and lamellar ichtyosis (TGM1) ( Table 2 ). In the transglutaminase family F13A1, TGM3 and TGM6 have some SNPs (3-4) with high frequency occurrence (over 10%) in the population while TGM2 and TGM1 have very low polymorphism. Regarding common variants the significance of Val34Leu polymorphism of Factor XIIIa have been assessed and was found to provide protection against myocardial infarction (Muszbek et al. 2010) . The enzyme activity of the Val34Leu variant does not change but its thrombin activation is quicker than that of the most frequent sequence variant (Kohler et al. 1998; Var et al. 2009 ). Another frequent variant of Factor XIIIa is Pro564Leu (Anwar et al. 1999; Saha et al. 2000) with higher enzymatic activity but no physiologic or pathologic association. The numbers of variants of other transglutaminases in the databases are fewer than 40. Among them there are two interesting mutations in TGM5 which show association with the Acral Peeling Skin Syndrome (Gly113Cys, Cassidy et al. 2005; Trp255Arg, Lys445Asn, Kharfi et al. 2009 ). In order to compare the diversity in the coding sequences of the transglutaminase family genes, we used the Complete Genomics diversity panel high coverage sequence data (Table 3) . We counted the number of the observed diverse loci in each reference gene transcript and normalized the results based on the length of the proteins. We have also counted the number of individuals out of 46 examined genomes who are homo-or heterozygous on the given locus. The data show clearly that among the examined gene transcripts the TGM2 NM_198951 transcript has the lowest missense number per 100 amino acids, while the compatible (silent or synonymous) mutation rate of this transcript is at average. This proves that the TGM2 protein is under a great purifying selective evolutionary pressure, which eliminates most of the missense mutations from the population. The reason for this strong evolutionary constraint is most likely the multiple, important functions of the protein in various cell compartments and outside of cells (Fesus and Piacentini 2002) . It is also worth to note, however, that both the TGM2 and the EPB42 genes, which have the lowest mutation rate (Table 3) , have two annotated transcript and protein form. This would cause increased selectional pressure on different parts of the proteins and thus can explain partly the lower than average mutational rate.
Conclusions
Analysis of the available genomic databases clearly show that the protein coding sequence of human transglutaminase 2 has very low polymorphism in the population and it has the lowest variability when compared to other members of the human transglutaminase family. According to functional studies of the rare protein variants, which so far have been found encoded only as heterozygous forms in genomes, the amino acid changes lead to defective proteins. This raises the possibility that they contribute to the development of pathologic conditions that will be very difficult to find considering their very low frequency of occurrence. Based on these conclusions, there is another important issue to address: how it is possible that while there is such a strong evolutionary pressure on human TGM2, the homozygous deletion of the mouse TGM2 does not result in life threatening phenotypes and these mice are fertile. Obviously, this and similar questions will generate exciting studies in the future resulting in important novel findings in human physiology and pathology.
